Malignant Ovarian Neoplasm

The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors we… (full text at CIViC)

PMID 16467099 · Gréen et al., 2006 · Open in CIViC

The ABCG2 Q141K variant was correlated with higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.

PMID 22112610 · Tian et al., 2012 · Open in CIViC

High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A2780cis ovarian cancer cell line showed that overexpression… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC)

PMID 20942669 · Wiegand et al., 2010 · Open in CIViC

Treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. ARID1A deficiency contributes to impaired MMR a… (full text at CIViC)

PMID 29736026 · Shen et al., 2018 · Open in CIViC

ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cel… (full text at CIViC)

PMID 17088436 · Lorenzi et al., 2006 · Open in CIViC

Preclinical evidence for epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy suggesting that silencing of ASS1 contributes to treatment failure and clinical relapse i… (full text at CIViC)

PMID 19533750 · Nicholson et al., 2009 · Open in CIViC

A high-throughput screening (HTS) strategy based on synthetic lethality was used to identify drugs that reduce cisplatin resistance in IGROV-CP20 cells, assessed via an MTT colorimetric assay. Various… (full text at CIViC)

PMID 32155756 · Mariniello et al., 2020 · Open in CIViC

To investigate the role of ATP7B in cisplatin resistance, the IGROV-CP20 ovarian cancer cell line was compared to its parental cisplatin-sensitive IGROV line. IGROV-CP20 cells exhibited significantly … (full text at CIViC)

PMID 32155756 · Mariniello et al., 2020 · Open in CIViC

In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expressio… (full text at CIViC)

PMID 19157502 · Mendiola et al., 2009 · Open in CIViC

A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC)

PMID 27209210 · Mignogna et al., 2016 · Open in CIViC

One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC)

Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC)

PMID 31105696 · Zhang et al., 2019 · Open in CIViC

In a clinical study of 49 patients, 29 patients with Ovarian Cancer and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of 8 weeks (95% CI, 6.… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undi… (full text at CIViC)

PMID 23346317 · Goff, 2013 · Open in CIViC

In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC)

PMID 28242752 · de Bono et al., 2017 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC)

PMID 26740259 · Harter et al., 2016 · Open in CIViC

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 302… (full text at CIViC)

PMID 24137399 · Salgado et al., 2013 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%C… (full text at CIViC)

PMID 21920589 · Carser et al., 2011 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC)

PMID 23346317 · Goff, 2013 · Open in CIViC

In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC)

PMID 28242752 · de Bono et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC)

PMID 26740259 · Harter et al., 2016 · Open in CIViC